- Open Access
Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells
Breast Cancer Research volume 20, Article number: 98 (2018)
- The original article was published in Breast Cancer Research 2007 9:R50
After the publication of this work , an error was noticed in Fig. 2b and Fig. 4b as well as Fig. 5d. and Fig. 5d. Images of the ERK1/2 blots were accidentally duplicated. In Fig. 5a. and Fig. 5c., the last lane for p-ERK1/2 was mistakenly cropped out of the final image. The original blot for Fig. 4b., “total EGFR” (or lane 2) is shown below to avoid any misunderstanding of the data. We apologize for this error, which did not affect any of the interpretations or conclusions of the article.
Fig. 4b. Uncropped original blot of “total EGFR” suggests that total EGFR levels increase with gefitinib treatment. However, increases in EGFR expression in response to gefitinib, are not seen across the study, which would suggest this increase is simply an anomaly.
Nicholson IR, et al. Heregulin β1 drives gefitinib-resistant growth, and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res. 2007;9(4):R50.
About this article
Cite this article
Hutcheson, I.R., Knowlden, J.M., Hiscox, S.E. et al. Correction to: Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res 20, 98 (2018). https://doi.org/10.1186/s13058-018-0999-6